Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several withdrawal-related statements are unsupported or overly specific (duration ranges, study citation, 2–4 week taper) and some severe outcomes are not supported by the provided label excerpts; indication statements are largely aligned with labeled uses.
Category Scores
Accurate Statements
Cymbalta is used to treat depression.
Indications and Usage: Major depressive disorder in adults
Cymbalta is used to treat anxiety.
Indications and Usage: Generalized anxiety disorder in adults and pediatric patients 7 years of age and older
Cymbalta is used to treat fibromyalgia.
Indications and Usage: Fibromyalgia in adults and pediatric patients 13 years of age and older
When stopping Cymbalta, patients may experience withdrawal symptoms.
Warnings and Precautions 5.7 Discontinuation Syndrome: discontinuation symptoms after abrupt or tapered discontinuation
Common Cymbalta withdrawal symptoms include dizziness.
5.7 Discontinuation Syndrome: dizziness
Common Cymbalta withdrawal symptoms include headache.
5.7 Discontinuation Syndrome: headache
Common Cymbalta withdrawal symptoms include nausea or vomiting.
5.7 Discontinuation Syndrome: nausea, vomiting
Tapering off Cymbalta can help minimize withdrawal symptoms.
Warnings and Precautions 5.7: 'A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible.'
Tapering off Cymbalta should be done under the guidance of a healthcare professional.
5.7 Discontinuation Syndrome: 'If intolerable symptoms occur... If intolerable symptoms occur... then resuming... may be considered. Subsequently, the healthcare provider may continue decreasing the dose...'
Tapering schedules for Cymbalta should be determined based on individual factors.
5.7 Discontinuation Syndrome: provider may continue decreasing the dose 'at a more gradual rate' based on patient response (implied by intolerance after decrease) in provided excerpt
Unsupported Statements
Cymbalta is used to treat nerve pain.
Label provided supports 'diabetic peripheral neuropathic pain in adults,' which is narrower than 'nerve pain.'
Cymbalta withdrawal symptom duration varies depending on dosage, treatment duration, and individual response.
Not supported by the provided label excerpts.
Cymbalta withdrawal symptoms can last anywhere from a few days to several weeks.
Not supported by the provided label excerpts.
Some people may experience Cymbalta withdrawal symptoms for a few weeks.
Not supported by the provided label excerpts.
Some people may experience Cymbalta withdrawal symptoms for several months.
Not supported by the provided label excerpts.
A study in the Journal of Clinical Psychopharmacology found the median duration of Cymbalta withdrawal symptoms was approximately 4-6 weeks.
Non-label quantitative duration claim not supported by the provided label excerpts.
Common Cymbalta withdrawal symptoms include flu-like symptoms such as chills and fever.
Chills/fever are not included among the discontinuation symptoms listed in the provided label excerpts.
In severe cases, Cymbalta withdrawal can lead to psychosis.
Psychosis is not included among the discontinuation symptoms or severe outcomes in the provided label excerpts.
In severe cases, Cymbalta withdrawal can lead to heart problems.
Heart problems are not included among the discontinuation symptoms or severe outcomes in the provided label excerpts.
A gradual reduction in Cymbalta dosage over a period of 2-4 weeks can help reduce the severity and duration of withdrawal symptoms.
Time-bound taper duration (2–4 weeks) and any claim about 'severity and duration' reduction are not supported by the provided label excerpts.
SSRIs can interact with Cymbalta.
No provided label excerpt states that SSRIs interact with Cymbalta.
Taking MAOIs during Cymbalta withdrawal can exacerbate withdrawal symptoms.
No provided label excerpt supports that specific exacerbation during withdrawal.
Taking SSRIs during Cymbalta withdrawal can exacerbate withdrawal symptoms.
No provided label excerpt supports that specific exacerbation during withdrawal.
Contradictions
Low
AI Statement
Some people may experience Cymbalta withdrawal symptoms for several months.
Label Reference
N/A (label provided does not give a duration ceiling); marked as unsupported rather than contradictory.
Important Omissions
The label excerpt emphasizes monitoring for discontinuation symptoms and considering resuming the previously prescribed dose if intolerable symptoms occur (with subsequent more gradual taper). This is not addressed in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported quantitative duration and specific taper timeframe (2–4 weeks), plus unsupported severe outcomes (psychosis/heart problems) and unsupported interaction/exacerbation claims could mislead expectations around discontinuation risk and management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple discontinuation-related details (duration ranges, study citation, 2–4 week taper) and severe outcomes/interaction-exacerbation claims are not supported by the provided label excerpts.
Suggested Improvement
Restrict discontinuation content to symptoms listed in 5.7 and the general recommendation to taper gradually (without specifying durations like weeks/months or a 2–4 week schedule unless explicitly present in the provided label). For drug interactions, use only the MAOI switching/washout interval statements shown in the provided label excerpts; avoid broad 'SSRIs interact' and withdrawal-exacerbation assertions not present in the excerpts.